As February 2026 begins, U.S. stock markets have shown strength, with major indexes like the Dow Jones and S&P 500 posting notable gains. In this context of market optimism and economic developments, investors are exploring opportunities across various sectors. Penny stocks, despite their somewhat outdated moniker, remain relevant as they often represent smaller or newer companies that can offer unique growth potential at lower price points. When backed by strong financials and solid fundamentals, these stocks can present a compelling investment opportunity for those willing to explore beyond the more prominent names in the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$3.19	$655.77M	✅ 3 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.80	$625.68M	✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)	$0.7405	$132.69M	✅ 4 ⚠️ 1 View Analysis >
LexinFintech Holdings (LX)	$2.70	$471.14M	✅ 4 ⚠️ 1 View Analysis >
Tuya (TUYA)	$2.06	$1.26B	✅ 4 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Cricut (CRCT)	$4.41	$961.32M	✅ 2 ⚠️ 2 View Analysis >
Nephros (NEPH)	$4.26	$48.56M	✅ 3 ⚠️ 2 View Analysis >
BAB (BABB)	$0.954975	$6.88M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$3.20	$72.5M	✅ 3 ⚠️ 2 View Analysis >

Let's explore several standout options from the results in the screener.

Gaxos.ai (GXAI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Gaxos.ai Inc. develops artificial intelligence applications and has a market cap of $10.04 million.

Operations: GXAI generates revenue of $0.69 million from its Computer Graphics segment.

Market Cap: $10.04M

Gaxos.ai, with a market cap of US$10.04 million and revenue of US$0.69 million, is pre-revenue and unprofitable but debt-free with sufficient cash runway for 2.2 years. Recent developments include AWS funding for an AI sales coaching platform, positioning the company in the lucrative sales technology market. Additionally, Gaxos launched God Pray AI for spiritual growth and expanded its Art-Gen platform with Photoshoots to enhance its presence in the creator economy. Despite high volatility and a lack of experienced management or board members, these initiatives could potentially drive future growth amidst current financial challenges.

Eventbrite (EB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Eventbrite, Inc. operates a two-sided marketplace offering self-service ticketing and marketing tools for event creators globally, with a market cap of approximately $443.92 million.

Operations: The company's revenue is primarily derived from its Internet Software & Services segment, totaling $294.80 million.

Market Cap: $443.92M

Eventbrite, Inc., with a market cap of US$443.92 million, is undergoing acquisition by Bending Spoons US Inc. for approximately US$500 million, transitioning to a privately held entity. Despite being unprofitable, Eventbrite has reduced losses over five years and maintains sufficient cash runway due to positive free cash flow. Recent earnings showed improved net income and narrowed revenue guidance for 2025 at US$290-293 million. The company's short-term assets exceed liabilities, indicating financial stability amidst high share price volatility and increased debt-to-equity ratio over time. The seasoned management team supports operational continuity during this transition phase.

Radnostix (INIS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Radnostix, Inc. operates in the nuclear medicine and life sciences sectors by manufacturing and selling calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug products, and radiochemicals both domestically and internationally, with a market cap of $38.56 million.

Operations: The company's revenue is primarily derived from Theranostics Products ($6.93 billion), Calibration & Reference Products ($4.72 billion), and Cobalt Products ($2.24 billion).

Market Cap: $38.56M

Radnostix, Inc., with a market cap of US$38.56 million, operates in the nuclear medicine and life sciences sectors but is currently unprofitable and pre-revenue. The company faces financial challenges, with short-term assets of US$5 million not covering long-term liabilities of US$10.1 million, although it maintains a cash runway exceeding three years based on current free cash flow. Recent earnings reports show increasing losses over the past year and five years at 43.5% annually. Despite these setbacks, Radnostix's board is experienced, though its share price remains highly volatile amidst high debt levels and negative equity returns.

Taking Advantage

• Jump into our full catalog of 336 US Penny Stocks here.
• Curious About Other Options? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.